Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (33,824) $ (4,344)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 3,404 3,796
Amortization of premium (accretion of discount) on marketable securities (166) 116
Stock-based compensation 802 1,126
Revaluation of SutroVax option liability 48 75
Revaluation of redeemable convertible preferred stock warrant liability (839) 186
Accretion of debt discount 119 24
Loss on disposal of property and equipment 35 87
Other revenue 140 0
Changes in operating assets and liabilities:    
Accounts receivable (819) (10,279)
Prepaid expenses and other current assets (901) (302)
Accounts payable (135) 178
Accrued compensation 446 (178)
Other liabilities 1,097 106
Deferred rent 45 56
Deferred revenue 49,166 (22,881)
Net cash provided by (used in) operating activities 18,618 (32,234)
Cash flows from investing activities:    
Purchases of marketable securities (81,456) (5,019)
Maturities of marketable securities 0 32,650
Sales of marketable securities 0 6,000
Purchases of property and equipment (759) (2,659)
Net cash provided by (used in) investing activities (82,215) 30,972
Cash flows from financing activities:    
Proceeds from issuance of debt 0 15,000
Payments of debt issuance fees 0 (171)
Payments of deferred offering costs (2,413) (74)
Proceeds from payment of note receivable by stockholder 208 0
Proceeds from issuances of common stock upon exercise of warrants 2 0
Proceeds from issuances of common stock upon exercise of stock options 394 61
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 84,739 0
Net cash provided by financing activities 82,930 14,816
Net increase in cash and cash equivalents 19,333 13,554
Cash, cash equivalents, and restricted cash—beginning of period 22,035 11,868
Cash, cash equivalents, and restricted cash—end of period 41,368 25,422
Supplemental disclosure of cash flow information:    
Cash paid for interest 942 184
Supplemental disclosure of non-cash investing and financing information:    
Vesting of early exercised shares 14 65
Purchase of property and equipment included in accounts payable 610 229
Deferred initial public offering costs included in accounts payable $ 1,659 $ 85